XBI: Biotech M&A Has Been Hot, But Price Trends Have Cooled

Mike Zaccardi, CFA, CMT9.07K FollowersFollow5ShareSavePlay(7min)CommentsSummaryI reiterate a Hold rating on State Street SPDR S&P Biotech ETF due to fair valuation and mixed technicals.XBI's recent outperformance has faded, with higher interest rates and a less risk-on market weighing on absolute and relative strength.At 19.3x P/E and just 3.2% long-term EPS growth, XBI lacks compelling value or growth catalysts near term.Buying XBI on a pullback to the $106–$110 range offers a more attractive risk/reward, especially as favorable seasonal trends may emerge mid-year. Solskin/DigitalVision via Getty Images Biotech stocks were on a heater coming off the April 2025 lows.

The State Street SPDR S&P Biotech ETF (XBI) sharply outperformed the S&P 500 Trust ETF (SPY) and the StateThis article was written byMike Zaccardi, CFA, CMT9.07K FollowersFollowFreelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passion is putting a narrative to financial data. Working with teams that include senior editors, investment strategists, marketing managers, data analysts, and executives, I contribute ideas to help make content relevant, accessible, and measurable. Having expertise in thematic investing, market events, client education, and compelling investment outlooks, I relate to everyday investors in a pithy way. I enjoy analyzing stock market sectors, ETFs, economic data, and broad market conditions, then producing snackable content for various audiences. Macro drivers of asset classes such as stocks, bonds, commodities, currencies, and crypto excite me. My thing is communicating finance with an educational and creative style. I also believe in producing evidence-based narratives using empirical data to drive home points. Charts are one of the many tools I leverage to tell a story in a simple but engaging way. I focus on SEO and specific style guides when appropriate.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.